Applications of gene therapy for familial amyloidotic polyneuropathy

Bibliography

• ANDRADE C: A peculiar form ofperipheral neuropathy: familial generalized amyloidosis with special involvement of the peripheral nerves. Biafra (1952) 75(3):408–427.
   Google Scholar
• •First report of patients with FAP.
   Google Scholar
• ARAKI S: Type I familial amyloidotic polyneuropathy (Japanese type). Biafra. Dev. (1984) 6(2):128–133.
   Web of Science ®Google Scholar
• ANDERSSON R: Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med. Scand. (1976) 590:1–64.
   Google Scholar
• BENSON MD: Familial amyloidotic polyneuropathy. Trends. Neurosci. (1989) 12(3):88–92.
   PubMed Web of Science ®Google Scholar
• BENSON MD, UEMICHI T:Transthyretin amyloidosis. Amyloid (1996) 3(1):44–56.
   Web of Science ®Google Scholar
• CONNORS LH, LIM A, PROKAEVA T, ROSKENS VA, COSTELLO CE: Tabulation of human transthyretin (TTR) variants, 2003. Amyloid (2003) 10(3):160–184.
   PubMed Web of Science ®Google Scholar
• TAWARA S, NAKAZATO M, KANGAWA K, MATSUO H, ARAKI S: Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type).Biochem. Biophys. Res. Commun. (1983) 116(3):880–888.
   Google Scholar
• AZUMA T, SUZUKI T, MIZUNO R et al.: Studies of neurocirculatory effects of long-term L-threo-3,4-dihydroxyphenylserine administration in a patient with familial amyloidotic polyneuropathy. Acta Neural. Scand. (1988) 77(5):409–413.
   PubMed Web of Science ®Google Scholar
• ADACHI N: Current and proposed treatment of familial amyloidotic polyneuropathy. Clin. Neuropharmacol. (1989) 12(6):506–513.
   PubMed Web of Science ®Google Scholar
• SALES-LUIS ML, GALVAO M, CARVALHO M, SOUSA G, ALVES MM, SERRAO R: Treatment of familial amyloidotic polyneuropathy (Portuguese type) by plasma exchange. Muscle Nerve (1991) 14(4):377–378.
   PubMed Web of Science ®Google Scholar
• REGNAULT V, COSTA PM, TEIXEIRA A et al.: Specific removal of transthyretin from plasma of patients with familial amyloidotic polyneuropathy:optimization of an immunoadsorption procedure. hat. Artil Organs. (1992) 15(0249–255.
   PubMed Web of Science ®Google Scholar
• CARVALHO M, ALVES M, LUIS ML: Octreotide-a new treatment for diarrhoea in familial amyloidotic polyneuropathy. Neural. Neurosurg. Psychiatry (1992) 55(9):860–861.
   PubMed Web of Science ®Google Scholar
• ANDO Y, GOTOH T, KAWAGUCHI Y, TANAKA Y, SAKASHITA N, ANDO M: Intranasal L-threo-3,4,-dihydroxyphenylserine in treating diarrhea associated with familial amyloidotic polyneuropathy. Pharmacotherapy (1995) 15(3):345–349.
   PubMed Web of Science ®Google Scholar
• HOLMGREN G, ERICZON BG, GROTH CG et al.: Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet (1993) 341(8853):1113–1116.
   PubMed Web of Science ®Google Scholar
• •First report on liver transplantation in FAP.
   Google Scholar
• ERICZON BG, HOLMGREN G, LUNDGREN E, SUHR OB: New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders & the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umea, Sweden, June 1999. Amyloid (2000) 7(2):145–147.
   Google Scholar
• SKINNER M, LEWIS WD, JONES LA et al.: Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann. Intern. Med. (1994) 120(2):133–134.
   PubMed Web of Science ®Google Scholar
• TAKEI Y, IKEDA S, HASHIKURA Y, IKEGAMI T, KAWASAKI S: Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients. Ann. Intern. Med. (1999) 131(8):592–595.
   PubMed Web of Science ®Google Scholar
• ANDO Y, TANAKA Y, ANDO E et al.: Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I. Lancet (1995) 345(8943):195–196
   PubMed Web of Science ®Google Scholar
• SUHR O, DANIELSSON A, RYDH A, NYHLIN N, HIETALA SO, STEEN L: Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Dig. Dis. Sci. (1996) 41(10):1909–1914.
   PubMed Web of Science ®Google Scholar
• LENDOIRE J, TRIGO P, AZIZ H et al.: CUETO G, Liver transplantation in transthyretin familial amyloidpolyneuropathy: first report from Argentina. Amyloid (1999) 6(4):297–300.
   PubMed Web of Science ®Google Scholar
• ANDO Y, TERAZAKI H, HARAOKA K et al.: Presence of autoantibody against ATTRVa130Met after sequential liver transplantation. Transplantation (2002) 73(5):674–675.
   PubMedGoogle Scholar
• ANDO E, ANDO Y, HARAOKA K: Ocular amyloid involvement after liver transplantation for polyneuropathy. Ann. Intern. Med. (2001) 135(10):931–932.
   PubMed Web of Science ®Google Scholar
• SOMIARI S, GLASSPOOL-MALONE J, DRABICK JJ et al.: Theory and in vivo application of electroporative gene delivery. Mol. Ther. (2000) 2(3):178–187.
   PubMed Web of Science ®Google Scholar
• WARD M, WU J, CHIU JF: Experimental study of the effects of Optison concentration on sonoporation in vitro. Ultrasound Med. Biol. (2000) 26(7):1169–1175.
   PubMed Web of Science ®Google Scholar
• MILLER DL, PISLARU SV, GREENLEAF JE: Sonoporation: mechanical DNA delivery by ultrasonic cavitation. Somat. Cell Mol. Genet. (2002) 27(1-6):115–134.
   PubMedGoogle Scholar
• KAY MA, GLORIOSO JC, NALDINI L: Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. (2001) 7(1):33–40.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA M, HUANG L: Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. (2001) 12(8):861–870.
   PubMed Web of Science ®Google Scholar
• YANG Y, LI Q, ERTL HC, WILSON JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinantadenoviruses.Virol. (1995) 69(4):2004–2115.
   Web of Science ®Google Scholar
• YANG Y, WILSON JM: Clearance of adenovirus-infected hepatocytes by class-I restricted CD4+ CTLs in vivo. I Immunol. (1995) 155(5):2564–2570.
   PubMed Web of Science ®Google Scholar
• KAY MA, HOLTERMAN AX, MEUSE L et al.: Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat. Genet. (1995) 11(2):191–197.
   PubMed Web of Science ®Google Scholar
• VANDENDRIESSCHE T, COLLEN D, CHUAH MK: Biosafety of onco-retroviral vectors. Carr. Gene. Ther. (2003) 3(6):501–515.
   PubMedGoogle Scholar
• FELGNER PL, GADEK TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Nati Acad. Sci. USA (1987) 84(21):7413–7417.
   PubMed Web of Science ®Google Scholar
• THOMAS M, KLIBANOV AM: Non-viralgene therapy: polycation-mediated DNA delivery. Appl. Microbial. Biotechnol (2003) 62:27–34.
   PubMed Web of Science ®Google Scholar
• FUJIOKA K, TAKADA Y, SATO S, MIYATA T: Novel delivery system for proteins using collagen as a carrier material: the minipellet. J. Control. Release (1995) 33(2):307–315.
   Web of Science ®Google Scholar
• OCHIYA T, TAKAHAMA Y,NAGAHARA S et al: New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the minipellet. Nat. Med. (1999) 5(6):707–710.
   PubMed Web of Science ®Google Scholar
• ••This article demonstrated thatatelocollagen was a novel delivery vehicle for DNA in vivo.
   Google Scholar
• LEE CH, SINGLA A, LEE Y: Biomedical applications of collagen. Int. J. Pharm. (2001) 221(1-2):1–22.
   PubMed Web of Science ®Google Scholar
• YOON K, COLE-STRAUSS A,KMIEC EB: Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA DNA oligonucleotide. Proc. Natl. Acad. Sri. USA (1996) 93(5):2071–2076.
   PubMed Web of Science ®Google Scholar
• ••First report on gene conversion bychirnaeraplasts in vitro.
   Google Scholar
• COLE-STRAUSS A, YOON K, XIANG Y, BYRNE BC et al.: Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science (1996) 273(5280):1386–1389.
   PubMed Web of Science ®Google Scholar
• SHESELY EG, KIM HS, SHEHEE WR, PAPAYANNOPOULOU T,SMITHIES O, POPOVICH BW: Correction of a human beta S-globin gene by gene targeting. Proc. Natl. Acad. Sci. USA (1991) 88(10):4294–4298.
   PubMed Web of Science ®Google Scholar
• SNOUWAERT JN, BRIGMAN KK, LATOUR AM et al.: An animal model for cystic fibrosis made by gene targeting. Science (1992) 257(5073):1083–1088.
   PubMed Web of Science ®Google Scholar
• SMITHIES O, MAEDA N: Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. Proc. Natl. Acad. Sci. USA (1995) 92(12):5266–5272.
   PubMed Web of Science ®Google Scholar
• MOERSCHELL RP, TSUNASAWA S, SHERMAN F: Transformation of yeast with synthetic oligonucleotides. Proc. Natl. Acad. Sci. USA (1988) 85(2):524–528.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, MOERSCHELL RP, WAKEM LP, KOMAR-PANICUCCI S, SHERMAN F: Strand-specificity in the transformation of yeast with syntheticoligonucleotides. Genetics (1992) 131(4):811–819.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, MOERSCHELL RP, WAKEM LP, FERGUSON D, SHERMAN F: Parameters affecting the frequencies of transformation and co-transformation with synthetic oligonucleotides in yeast. Yeast (1992) 8(11):935–948.
   PubMed Web of Science ®Google Scholar
• KOTANI H, GERMANN MW, ANDRUS A, VINAYAK R, MULLAH B, KMIEC EB: RNA facilitates Rec-A-mediated DNA pairing and strand transfer between molecular bearing limited regions of homology. MM. Gen. Genet. (1996) 250(5):626–634.
   PubMed Web of Science ®Google Scholar
• •This article shows that RNA can reduce the length of homology required for strand exchange.
   Google Scholar
• COLE-STRAUSS A, GAMPER H, HOLLOMAN WK, MUNOZ M, CHENG N, KMIEC EB: Targeted gene repair directed by the chimeric RNA/DNA oligonucleotide in a mammalian cell-free extract. Nucleic Acid. Res. (1999) 27(5):1323–1330.
   PubMed Web of Science ®Google Scholar
• GAMPER HB JR, COLE-STRAUSS A, METZ R, PAREKH H, KUMAR R, KMIEC EB: A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry (2000) 39(19):5808–5816.
   PubMed Web of Science ®Google Scholar
• GAMPER HB, PAREKH H, RICE MC, BRUNER M, YOUKEY H, KMIEC EB: The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/ conversion activity in mammalian and plant cell-free extracts. Nucleic Acids Res. (2000) 28(21):4332–4339.
   PubMed Web of Science ®Google Scholar
• •This article reported that gene repair by SSOs was as effective as chimaeraplasts.
   Google Scholar
• LU H, FISHER RP, BAILEY P, LEVINE AJ: The CDK7-cycH-p36 complex of transcription Factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Ma Cell. Biol. (1997) 17(10):5923–5934.
   Web of Science ®Google Scholar
• RICE MC, CZYMMEK K, KMIEC EB: The potential of nucleic acid repair in functional genomics. Nat. Biotechnol (2001) 19(4):321–326.
   PubMed Web of Science ®Google Scholar
• LIU L, RICE MC, KMIEC EB: In vivo gene repair of point and frameshift mutations directed by chimeric RNA/DNA oligonucleotides and modified single-stranded oligonucleotides. Nucleic Acids Res. (2001) 29(20):4238–4250.
   PubMed Web of Science ®Google Scholar
• LIU L, CHENG S, VAN BRABANT AJ, KMIEC EB: Rad5lp and Rad54p, but not Rad52p, elevate gene repair in Saccharomyces cerevisiae directed by modified single-stranded oligonucleotide vectors. Nucleic Acids Res. (2002) 30(13):2742–2750.
   PubMed Web of Science ®Google Scholar
• •This article was the first to show that Rad51 stimulated gene repair in yeast.
   Google Scholar
• LIU L, RICE MC, DRURY M, CHENG S, GAMPER H, KMIEC EB: Strand bias in targeted gene repair is influenced by transcriptional activity. Ma Cell. Biol. (2002) 22(11):3852–3863.
   Web of Science ®Google Scholar
• METZ R, DICOLA M, KURIHARA T et al.: Mode of action of RNA/DNA oligonucleotides progress in the development of gene repair as a therapy for a(1)-antitrypsin deficiency. Chest (2002) 121(3 Suppl.):91–97.
   Google Scholar
• GAMPER HB, NULF CJ, COREY DR, KMIEC EB: The synaptic complex of RecA protein participates in hybridization and inverse strand exchange reactions. Biochemistry (2003) 42(9):2643–2655.
   PubMed Web of Science ®Google Scholar
• BRACHMAN EE, KMIEC EB: Targeted gene repair of cyc I mutations in Saccharomyces cerevisiae directed by modified single-stranded DNA oligonucleotides. Genetics (2003) 163(2):527–538.
   PubMed Web of Science ®Google Scholar
• ANDERSEN MS, SORENSEN CB, BOLUND L, JENSEN TG: Mechanisms underlying targeted gene correction using chimeric RNA/DNA and single-stranded DNA oligonucleotides. Ma Med. (2002) 80(12):770–781.
   Google Scholar
• ••This article is a valuable review ofoligonucleotide targeting, including the mechanisms involved.
   Google Scholar
• PROPSTING MJ, BLASCHKE M, HAAS RE et al: Inosine(15.1)-Hammerhead ribozymes for targeting the transthyretin-30 mutation.Biochem. Biophys. Res. Commun. (1999) 260 (2) :313–317.
   Google Scholar
• TANAKA K, YAMADA T, OHYAGI Y, ASAHARA H, HORIUCHI I, KIRA J: Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. Neurol. Sci. (2001) 183(1):79–84.
   Web of Science ®Google Scholar
• •This article shows the possibility of gene therapy by ribozymes in FAP.
   Google Scholar
• ANDO Y, YAMASHITA T,NAKAMURA M et al.: Down regulation of a harmful variant protein by replacement of its normal protein. Biochim. Biophys. Acta (1997) 1362(1):39–46.
   Google Scholar
• JOUQUAN J, PENNEC Y, MOTTIER D et al.: Retinol carrier protein, prealbumin and transferrin. Influence of age and sex on the serum concentration of proteins with a short half-life. Presse Med. (1983) 12(30):1877.
   Google Scholar
• DICKSON PW, HOWLETT GJ, SCHREIBER G: Metabolism of prealbumin in rats and changes induced by acute inflammation. Eur.j Biochem. (1982) 129(2):289–293.
   PubMedGoogle Scholar
• ANDO Y, TANAKA Y, NAKAZATO M et al.: Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem. Biophys. Res. Commun. (1995) 211(2):354–358.
   PubMed Web of Science ®Google Scholar
• KREN BT, BANDYOPADHYAY P, STEER CJ: In vivo site-directedmutagenesis of the Factor IX gene by chimeric RNA/DNA oligonucleotide. Nat. Med. (1998) 4(3):285–290.
   PubMed Web of Science ®Google Scholar
• •This article shows in vivo effect of chirnaeraplasts in animals.
   Google Scholar
• KREN BT, PARASHAR B, BANDYOPADHYAY P, CHOWDHURY NR, CHOWDHURY JR, STEER CJ: Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide. Proc. Natl. Acad. Sci. USA (1999) 96(18):10349–10354.
   PubMed Web of Science ®Google Scholar
• NAKAMURA M, ANDO Y,NAGAHARA S et al: Targeted conversion of the transthyretin gene in vitro andM vivo. Gene Ther. (2004) 11(10):838–846.
   PubMed Web of Science ®Google Scholar
• ••This article was the first to present thepossibility of gene repair by SSOs in FAP.
   Google Scholar
• TAGALAKIS AD, GRAHAM IR, RIDDELL DR, DICKSON JG, OWEN JS: Gene conversion of the apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeraplasty. Biol. Chem. (2001) 276(16):13226–13230.
   Web of Science ®Google Scholar
• LIU L, PAREKH-OLMEDO H, KMIEC EB: The development and regulation of gene repair. Nat. Rev Genet. (2003) 4(9):679–689.
   PubMed Web of Science ®Google Scholar